Wuxi Biologics (Cayman) Inc. 2269
HKEX · Hong Kong SAR China · Health Technology
HKD 56.05+2.55 (+4.77%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030 The global recombinant proteins manufacturing services m
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its drug substance (DS) and drug product (DP) manufacturing facilities at the Wuxi Mashan site successfully passed a two-week GMP inspection conducted by the U.S. Food and Drug Administration (FDA). The successful inspection further strengthens the Company's capabilities to ensure the reliable supply of its partners' commercial products to the U.S. market.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.